David Arkowitz
CIK 1296999 · Chief Financial Officer · last filed 2026-10-15
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
FLXN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
10 MALL ROAD, SUITE 301
BURLINGTON, MA 01803
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IBIO | Director | 18,382 | $0.73 | $13.5K | $50.0K | 4 | 2026-10-15 |
| KINETA, INC./DE (KA) Delisted | Director | — | $0.57 | — | $0 | 2 | 2024-09-05 |
| MCRB | Chief Financial Officer | 9,122 | $1.84 | $16.8K | -$9.7K | 8 | 2024-02-16 |
| F-star Therapeutics, Inc. (FSTX) Delisted | Director | 0 | $7.12 | $0 | $0 | 3 | 2023-03-09 |
| KINETA, INC./DE (YMTX) Delisted | Director | 621 | $13.23 | $8.2K | $0 | 2 | 2021-06-04 |
| FLXN | Chief Financial Officer | 220,719 | $24.21 | $5.34M | $102.9K | 17 | 2021-05-12 |
| F-star Therapeutics, Inc. (SBPH) Delisted | Director | 9,482 | — | — | $30.6K | 12 | 2020-11-23 |
| KINETA, INC./DE (PTI) Delisted | Director | — | — | — | $0 | 2 | 2020-07-01 |
| AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | EVP, CFO and CBO | 1,806 | — | — | -$85.4K | 20 | 2011-06-01 |
| IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Chief Financial Officer | — | — | — | $0 | 1 | 2007-03-14 |
Recent Filings · Page 5 of 8
73 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-04-02 | F-star Therapeutics, Inc. (SBPH) Delisted | Grant (A) | +1,370 | $0 | EDGAR |
| 2019-03-08 | KINETA, INC./DE (PTI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-03-05 | FLXN | Grant (A) | +36,000 | $0 | EDGAR |
| 2019-01-04 | FLXN | Other (J) | +922 | $9.7K | EDGAR |
| 2018-11-13 | FLXN | Buy (P) | +4,000 | $66.2K | EDGAR |
| 2018-08-10 | FLXN | Buy (P) | +4,000 | $93.7K | EDGAR |
| 2018-06-19 | F-star Therapeutics, Inc. (SBPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-04 | FLXN | Grant (A) | +30,000 | $0 | EDGAR |
| 2017-08-07 | F-star Therapeutics, Inc. (SBPH) Delisted | Buy (P) | +2,500 | $30.6K | EDGAR |
| 2017-06-16 | F-star Therapeutics, Inc. (SBPH) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.